Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tonabersat for Diabetic Macular Edema
NCT05727891Phase 2Active, not recruiting
- Sponsor
- Jaeb Center for Health Research
- Start
- May 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic macular edema (DME) comparing Placebo with Tonabersat (80 mg) (2 arms). Primary endpoint: Central Subfield Thickness at 6 months. Started May 2023; status: active, not recruiting.
02
Drugs
tonabersat
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT05727891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05727891.